Skip to main content
. Author manuscript; available in PMC: 2014 Feb 24.
Published in final edited form as: Anat Physiol. 2012 Jun 25;Suppl 12:001. doi: 10.4172/2161-0940.s12-001

Figure 1. Prevalence of hyperplastic alveolar nodules (HANs) and invasive adenocarcinomas in one-year-old mice over-expressing ERα (CERM), cyclin D1 (D1), both ERα and D1 (CERM/D1) mice in no-treatment and DMBA and tamoxifen intervention groups.

Figure 1

(A) Bar graphs comparing the prevalence of at least one HAN, multiple HANs, and invasive cancers in one-year-old CERM, CERM/D1, D1 and WT mice that received no treatment intervention. (B) Bar graphs comparing the prevalence of at least one HAN, multiple HANs, and invasive cancers in one-year-old CERM, CERM/D1, and D1 mice that were exposed to a single-dose of DMBA intervention at four months of age. (C) Bar graphs comparing the prevalence of at least one HAN, multiple HANs, and invasive cancers in one-year-old CERM, CERM/D1, D1 and WT mice that received tamoxifen treatment intervention at ten months of age. * indicates statistically significant differences (Fisher’s exact test, one tailed, p≤0.05).